Cytiva

Cytiva is a global leader in life sciences, providing a broad range of technologies and services that advance and accelerate the development and manufacture of therapeutics. Formerly GE Healthcare Life Sciences, the company was rebranded as Cytiva following its $21.4 billion acquisition by Danaher Corporation in April 2020. In 2023, Cytiva completed a major integration with Pall Corporation's Life Sciences business, significantly expanding its portfolio to include market-leading brands like ÄKTA, Amersham, Biacore, and Pall's filtration solutions. The company serves as a critical supplier and technology partner to the pharmaceutical and biotechnology industries. Its offerings span the entire bioprocessing spectrum, including discovery, process development, and large-scale manufacturing across various modalities such as monoclonal antibodies, cell and gene therapies, and mRNA. Cytiva's infrastructure is vital to the industry; in 2019, more than 75% of biological therapies approved by the FDA utilized Cytiva’s technologies for manufacturing.